The time-dependent and dosage-specific effects of sorafenib on tumor invasion may be due to differences in the regulation pattern of the effect of IL-6 on HIF-1α, namely, positive regulation in the early stage and negative regulation in the later stage. Here, HIF1A is linked to neoplasm.